CD274 and non-small cell lung carcinoma: The FDA has approved PD-L1 expression analysis as a diagnostic marker for anti-PD-1 therapy in patients with non-small-cell lung carcinoma (NSCLC), and pembrolizumab is an example of a drug approved for patients with PD-L1-expressing NSCLC.